(Q51811423)

13 April 2018

title

Cardiomyopathy in tyrosinaemia type I is common but usually benign. (English)

1 reference

13 April 2018

author name string

N Arora

1

1 reference

13 April 2018

O Stumper

2

1 reference

13 April 2018

J Wright

3

1 reference

13 April 2018

D A Kelly

4

1 reference

13 April 2018

P J McKiernan

5

1 reference

13 April 2018

publication date

1 February 2006

1 reference

13 April 2018

Journal of Inherited Metabolic Disease

published in

1 reference

13 April 2018

volume

29

1 reference

13 April 2018

issue

1

1 reference

13 April 2018

page(s)

54-57

1 reference

13 April 2018

Cardiac involvement in mitochondrial diseases. A study on 17 patients with documented mitochondrial DNA defects

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10545-006-0203-5

Clinical and pathologic study of familial dilated cardiomyopathy

21 January 2018

1 reference

12 December 2020

The occurrence of hepatoma in the chronic form of hereditary tyrosinemia

1 reference

12 December 2020

Cardiomyopathies: from genetics to the prospect of treatment

1 reference

12 December 2020

On the enzymic defects in hereditary tyrosinemia

1 reference

12 December 2020

Tyrosinaemia type I and hypertrophic obstructive cardiomyopathy

1 reference

12 December 2020

Cardiac alterations in cirrhosis: reversibility after liver transplantation

1 reference

12 December 2020

Hemodynamic effects of 5-aminolevulinic acid in humans.

1 reference

12 December 2020

X-linked dilated cardiomyopathy

1 reference

12 December 2020

Type I tyrosinemia: lack of immunologically detectable fumarylacetoacetase enzyme protein in tissues and cell extracts

1 reference

12 December 2020

Delta-Aminolevulinic acid synthetase in the heart

1 reference

12 December 2020

Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase

1 reference

12 December 2020

Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies.

1 reference

12 December 2020

Nontransplant treatment of tyrosinemia

1 reference

12 December 2020

Hereditary tyrosinemia type I: a new clinical classification with difference in prognosis on dietary treatment.

1 reference

12 December 2020

Changes of Myocardial Functions in Acute Hepatic Porphyrias. Role of Heme Arginate Administration

1 reference

12 December 2020

The kidney in children with tyrosinemia: sonographic, CT and biochemical findings.

1 reference

12 December 2020

Mutation screening for tyrosinaemia type I

1 reference

12 December 2020

Indications and outcome of liver transplantation in tyrosinaemia type 1

1 reference

12 December 2020

Cirrhotic cardiomyopathy: a pathophysiological review of circulatory dysfunction in liver disease

1 reference

12 December 2020

Echocardiographic abnormalities in the mucopolysaccharide storage diseases.

1 reference

12 December 2020

Gross cardiac involvement in glycogen storage disease type 3

1 reference

12 December 2020

Evolution of a hereditary cardiac conduction and muscle disorder: a study involving a family with six generations affected

1 reference

12 December 2020

Different clinical forms of hereditary tyrosinemia (type I) in patients with identical genotypes

1 reference

12 December 2020

Successful treatment of severe cardiomyopathy with NTBC in a child with tyrosinaemia type I.

1 reference

12 December 2020

Cardiovascular involvement in patients with liver cirrhosis

1 reference

12 December 2020

Tyrosinemia: a review

1 reference

12 December 2020

Heme biosynthesis in the heart

1 reference

12 December 2020

Tyrosinaemia type I and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione).

1 reference

12 December 2020

10.1007/S10545-006-0203-5

Identifiers

DOI

1 reference

13 April 2018

1 reference

13 April 2018